AmeriHealth will make changes to its Select Drug Program® Formulary and Value Formulary effective July 1, 2024. The changes include Brand and Generic additions and tier changes.
AmeriHealth in New Jersey
AmeriHealth in Pennsylvania
The two changes affecting the largest number of members are to the Value Formulary and involve two drugs used for glycemic control for diabetics, and one drug for the treatment of migraines.
Invokana® and Invokamet [XR]®, sodium-glucose co-transporter 2 (SGLT2) inhibitors, will be removed from the Value Formulary (non-formulary). Invokana® and Invokamet [XR]® are indicated:
-
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
-
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
-
To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria
Emgality® 120 mg/mL is an injectable calcitonin-gene related peptide antagonist will be removed from the Value Formulary (non-formulary). Emgality® 120 mg/mL is indicated in adults for:
-
preventive treatment of migraine
-
treatment of episodic cluster headache
You can review the full formularies on our website, where you can download a PDF or search for a specific formulary drug.
To view Select Drug Formulary information for your patients who may carry an AmeriHealth Administrators ID card, visit the AmeriHealth Administrators website.
For more on pharmacy policies and programs, visit our website.